Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. - Wikidata - awgldk - TriplyDB

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

http://www.wikidata.org/entity/Q33367606

about

Hepatitis C virus and allogeneic stem cell transplantation still matters!Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation Review article: management of hepatic disease following haematopoietic cell transplant.Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents.Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy.Hepatitis C in haematological patients.Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant.Prevention and treatment of hepatitis virus infections in hematopoietic stem cell transplant recipients Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation.Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy.Treatment of hepatitis C in a pediatric patient using simeprevir and sofosbuvir immediately after an umbilical cord blood transplantation.

P2860

Q27487854-D0CC788B-0154-4023-982D-38EC5FAD1321 Q28388806-7A26189A-EBEE-4918-99E2-B43153CDB115 Q30417045-2362539A-F12B-46B3-B40F-270569E4EC1B Q36347299-8B842AD8-4C5F-4464-8701-5F32E086526F Q36555955-335DF7E3-C2F6-48A0-9CA7-002A311AFF58 Q36790040-724BAFBF-2235-4672-B178-07C45B7A933F Q38062943-42368D69-040E-463C-8B48-8955D6191265 Q41218951-75A47F41-8FD5-4E32-A3B8-FDB53D699473 Q41678851-E15C8114-0F9C-43F5-84A8-61DD5BF6D374 Q41888846-E6B7C141-3B11-4630-A1E3-FBFEF9CEE02C Q42990029-139B10CD-C6A3-49C2-90C7-7F5AE03AFDDD Q50554156-03F0AD74-2897-40FD-A485-B97B5BB335D3 Q54687687-687E6212-B1EC-4FA1-80E2-D93EF8EB576A

P2860

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

http://www.wikidata.org/entity/Q33367606

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

@ast

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

@en

type

label

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

@ast

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

@en

prefLabel

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

@ast

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

@en

P1433

Q33367606-AFE474E4-9B52-4824-B1D6-5155A2CF90ED

P1476

Q33367606-1B5BCDAF-B0D5-4013-B45A-693EE79D4246

P2093

Q33367606-2364B24D-23F2-44F1-B2C2-A094B92E59A2

Q33367606-2A9B8E72-2B34-42DB-A2A9-8F86C48AFE2A

Q33367606-2AB4B7AE-C567-48E8-9734-014221DF7456

Q33367606-2DB8FE61-33C1-439E-9AF8-53077E6D5DDF

Q33367606-4AFE648A-9727-4518-B7C5-5C6D969679E9

Q33367606-6069C36D-A5B3-4D43-958C-323A86B9E5DC

Q33367606-BA56E230-DAFE-401E-9BAA-53F16C1B615F

Q33367606-D6C79497-8113-4220-9655-CF317A7BC42A

Q33367606-F2F39521-3D60-49E4-903E-8C8FB596800D

P2860

Q33367606-05213782-2801-405E-9616-09BADD283C84

Q33367606-05AFF300-31BD-4CC7-A10A-737DDF1BCDE8

Q33367606-0CBB6876-9487-455A-A986-06F7ACF2B5B1

Q33367606-0D8F9988-AE5C-407B-BD7A-C36A9243CA6A

Q33367606-20334F4D-8B01-483F-8412-3DE079451E4C

Q33367606-370CA911-302D-48E5-B5EC-824C9CF5AC18

Q33367606-418441C4-C083-43E1-96D3-523739734838

Q33367606-4281905A-7619-4594-AAB8-D4F3F9FF279D

Q33367606-4C217634-F141-448D-9183-C7EE6FDDD36E

Q33367606-9253343F-EDDF-4F8C-A6F0-E2CD919C4D04

P2888

Q33367606-27A57574-F4DD-4D7A-B072-6D29A8B79C6D

P304

Q33367606-B48FA273-01D6-4D6D-A00B-089C6F5A1740

P31

Q33367606-D6CCA90A-0D49-49E8-8E88-3795C561730D

P356

Q33367606-D1CC4BC6-BE4A-481B-91A1-20CE7B7641A9

P407

Q33367606-BEF88325-C266-478D-BEB7-48F444D150CE

P433

Q33367606-4A31C3ED-2A40-46E9-814B-19CB9714771D

P478

Q33367606-A17B79B2-600A-4A4A-A5C1-241A4EA38220

P50

Q33367606-227BC668-6188-41EF-BFEA-32354998B13D

Q33367606-4ED8D38B-EF53-48DF-A3E3-DFAE6A01AA84

Q33367606-E28983A4-DD99-4CD6-A7F2-0D5263CF8BF0

P577

Q33367606-8D81A3E8-7A3F-4F87-8FE8-DAADC50DC484

P6179

Q33367606-113F093E-EBDB-4729-B46B-180E5A1ED8A9

P698

Q33367606-D7864E68-5018-4B3E-8C8E-DB5DDFC8059A

P356

P1433

Bone Marrow Transplantation

P1476

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients

@en

P2093

Asselah T

http://www.w3.org/2001/XMLSchema#string

Devergie A

http://www.w3.org/2001/XMLSchema#string

Espérou H

http://www.w3.org/2001/XMLSchema#string

Marcellin P

http://www.w3.org/2001/XMLSchema#string

Peffault de Latour R

http://www.w3.org/2001/XMLSchema#string

Ribaud P

http://www.w3.org/2001/XMLSchema#string

Scieux C

http://www.w3.org/2001/XMLSchema#string

Socié G

http://www.w3.org/2001/XMLSchema#string

Traineau R

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Therapy of hepatitis C: patients with normal aminotransferase levels.

Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation.

Hepatitis C virus in long-term bone marrow transplant survivors.

Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination.

P2888

P304

709-713

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1705120

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Éliane Gluckman

Dominique C Valla

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011835449

http://www.w3.org/2001/XMLSchema#string

P698

16062173

http://www.w3.org/2001/XMLSchema#string